Behandlung chronischer Wunden mit einer semipermeablen hydroaktiven wundauflage

Chronic wounds are an increasing challenge for medicine and society. Treatment optimization aims to improve therapeutic and cost efficacy, compliance and tolerability. In an open, prospective trial 26 patients (mean age 69 years) with leg ulcers caused by chronic venous insufficiency (13), postthrombotic syndrome (9) or other causes (Diabetes mellitus, ulcerated scar, peripheral arterial occlusion disease - one patient each) were treated with a non-occlusive hydroactive wound dressing (Askina Transorbent®) for 6 weeks or until complete healing. Wound area (cm 2 ), granulation, necrosis and fibrin coverage (4-point score) were analyzed. Side effects were recorded. We noticed 5 drop outs (3 because of non-compliance, 1 because of pain, 1 because of hypergranulation). In the remaining 21 patients wound area was reduced from 11.2 cm 2 to 2.4 cm 2 . Eleven patients showed complete healing, 9 a more than 50% reduction of wound area, 1 patient had a reduction of wound area of less than 50%. Those patients with an incomplete healing on average had a wound area twice as large as complete responders. Granulation markedly increased during the first two weeks of treatment (1.8 vs. 4.0 score points). The fibrin coverage continuously decreased during the first 5 weeks (1.0 vs. 0.2 score points). Neither leakages, dermatitis nor mazeration of the perilesional skin were observed. No signs of disintegration of the dressing were found. Antibiotics were not used. The ulcer treatment with Askina Transorbent® is effective, safe and easily combinable with compression bandages.